한글목차

ZYNRELEF(구명 HTX-011)(부피바카인 멜록시컴)는 국소 아미드 마취제인 부피바카인과 비스테로이드성 항염증제(NSAID)인 멜록시컴을 포함하여 성인에서 외반모 발목 절제술, 살서제 탈장 개방술, 인공 슬관절 전치환술 수술 후 72시간까지 연부 조직 또는 관절 주위에 주입하여 수술 후 진통을 적응으로 하고 있습니다. 이 약물은 처음으로 유일한 서방형 이중 작용 국소 마취제(DALA)이며 바늘을 사용하지 않는 한 번의 적용으로 72 시간의 수술 후 진통을 초래합니다. 부피바카인과 멜록시 캠의 안정적인 전달을 위해 Heron의 독점적 인 제어 확산 Biochronomer 폴리머로 제형화되었습니다.

앞으로 몇 년동안 세계의 광범위한 조사와 의료비 증가로 수술 후 통증 시장 시나리오가 변할 것입니다. 각 회사는 병리를 치료/개선하기 위한 새로운 접근법에 중점을 둔 치료법을 개발하고, 과제를 평가하고, ZYNRELEF의 이점에 영향을 줄 수 있는 기회를 모색하고 있습니다. 수술후 통증을 대상으로 하는 다른 신흥제품은 ZYNRELEF와 엄격한 시장경쟁을 벌일 것으로 예상되며, 가까운 미래에 후발 신흥치료제가 상시되면 시장에 큰 영향을 미칠 것으로 보입니다.

본 보고서는 주요 7개국의 ZYNRELEF 시장에 대해 조사했으며,, 시장 개요와 함께 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등을 제공합니다.

목차

제1장 보고서 소개

제2장 수술후 통증에 있어서의 ZYNRELEF의 개요

• 제품 상세
• 임상 개발
• 규제 마일스톤
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법

제4장 경쟁 구도(후기 단계의 신흥 치료법

제5장 ZYNRELEF 시장 평가

• 수술 후 통증에서 ZYNRELEF 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 정보

제12장 보고서 구매 옵션

영문목차

"ZYNRELEF Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about ZYNRELEF for Postoperative pain in the seven major markets. A detailed picture of the ZYNRELEF for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ZYNRELEF for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZYNRELEF market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

ZYNRELEF (formerly known as HTX-011) (bupivacaine and meloxicam) contains bupivacaine, a local amide anesthetic, and meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), and is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 h after a bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. It is the first and only extended-release dual-acting local anesthetic (DALA) and delivers 72 h of postoperative pain relief via a single needle-free application. It is formulated in Heron's proprietary controlled-diffusion Biochronomer polymer for consistently regulated delivery of bupivacaine and meloxicam.

Dosage and administration

The recommended dose of ZYNRELEF is as follows:

• For bunionectomy: up to 2.3 mL to deliver 60 mg of bupivacaine and 1.8 mg of meloxicam.
• For open inguinal herniorrhaphy: up to 10.5 mL to deliver 300 mg of bupivacaine and 9 mg of meloxicam.
• For total knee arthroplasty: up to 14 mL to deliver 400 mg of bupivacaine and 12 mg of meloxicam.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ZYNRELEF description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on ZYNRELEF regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ZYNRELEF research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around ZYNRELEF.
• The report contains forecasted sales of ZYNRELEF for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for ZYNRELEF in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ZYNRELEF Analytical Perspective by DelveInsight

• In-depth ZYNRELEF Market Assessment

This report provides a detailed market assessment of ZYNRELEF for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• ZYNRELEF Clinical Assessment

The report provides the clinical trials information of ZYNRELEF for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZYNRELEF dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to ZYNRELEF and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZYNRELEF in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of ZYNRELEF from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ZYNRELEF in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of ZYNRELEF?
• What is the clinical trial status of the study related to ZYNRELEF in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZYNRELEF development?
• What are the key designations that have been granted to ZYNRELEF for Postoperative pain?
• What is the forecasted market scenario of ZYNRELEF for Postoperative pain?
• What are the forecasted sales of ZYNRELEF in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ZYNRELEF for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. ZYNRELEF Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ZYNRELEF Market Assessment

• 5.1. Market Outlook of ZYNRELEF in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ZYNRELEF in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ZYNRELEF in the United States for Postoperative pain
  • 5.3.2. Market Size of ZYNRELEF in Germany for Postoperative pain
  • 5.3.3. Market Size of ZYNRELEF in France for Postoperative pain
  • 5.3.4. Market Size of ZYNRELEF in Italy for Postoperative pain
  • 5.3.5. Market Size of ZYNRELEF in Spain for Postoperative pain
  • 5.3.6. Market Size of ZYNRELEF in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of ZYNRELEF in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options